HRP20160481T1 - Peptidi za cjepiva protiv alergije na brezu - Google Patents

Peptidi za cjepiva protiv alergije na brezu Download PDF

Info

Publication number
HRP20160481T1
HRP20160481T1 HRP20160481TT HRP20160481T HRP20160481T1 HR P20160481 T1 HRP20160481 T1 HR P20160481T1 HR P20160481T T HRP20160481T T HR P20160481TT HR P20160481 T HRP20160481 T HR P20160481T HR P20160481 T1 HRP20160481 T1 HR P20160481T1
Authority
HR
Croatia
Prior art keywords
variant
polypeptide
seq
sequence
preparation according
Prior art date
Application number
HRP20160481TT
Other languages
English (en)
Croatian (hr)
Inventor
Roderick Peter Hafner
Paul Laidler
Guy Layton
Mark Larche
Original Assignee
Circassia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Limited filed Critical Circassia Limited
Publication of HRP20160481T1 publication Critical patent/HRP20160481T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
HRP20160481TT 2010-02-15 2011-02-15 Peptidi za cjepiva protiv alergije na brezu HRP20160481T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1002559.1A GB201002559D0 (en) 2010-02-15 2010-02-15 Birch peptides for vaccine
EP11730036.8A EP2536429B1 (en) 2010-02-15 2011-02-15 Peptides for vaccines against birch allergy
PCT/GB2011/000206 WO2011098778A2 (en) 2010-02-15 2011-02-15 Peptides for vaccines against birch allergy

Publications (1)

Publication Number Publication Date
HRP20160481T1 true HRP20160481T1 (hr) 2016-06-03

Family

ID=42110757

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160481TT HRP20160481T1 (hr) 2010-02-15 2011-02-15 Peptidi za cjepiva protiv alergije na brezu

Country Status (20)

Country Link
US (2) US9017689B2 (cg-RX-API-DMAC7.html)
EP (2) EP3056213A1 (cg-RX-API-DMAC7.html)
JP (2) JP5926198B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120120965A (cg-RX-API-DMAC7.html)
CN (1) CN102762225B (cg-RX-API-DMAC7.html)
AU (1) AU2011214104B2 (cg-RX-API-DMAC7.html)
CA (2) CA2789353A1 (cg-RX-API-DMAC7.html)
DK (1) DK2536429T3 (cg-RX-API-DMAC7.html)
EA (1) EA201290792A1 (cg-RX-API-DMAC7.html)
ES (1) ES2573651T3 (cg-RX-API-DMAC7.html)
GB (2) GB201002559D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20160481T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029138T2 (cg-RX-API-DMAC7.html)
IL (1) IL221196A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012009431A (cg-RX-API-DMAC7.html)
NZ (1) NZ602380A (cg-RX-API-DMAC7.html)
PL (1) PL2536429T3 (cg-RX-API-DMAC7.html)
SG (1) SG183198A1 (cg-RX-API-DMAC7.html)
SI (1) SI2536429T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011098778A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
WO2013119853A1 (en) * 2012-02-07 2013-08-15 La Jolla Institute For Allergy And Immunology Epitopes from allergen proteins and methods and uses for immune response modulation
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
GB201211586D0 (en) * 2012-06-29 2012-08-15 Circassia Ltd Japanese cedar peptides for preventing or treating allergy
US20150088644A1 (en) 2013-09-23 2015-03-26 Facebook, Inc., a Delaware corporation Predicting User Interactions With Objects Associated With Advertisements On An Online System
CN106699584B (zh) * 2016-12-30 2018-06-26 南京农业大学 一种利用花粉作为天然催化剂制备的γ-氨基丁酸及其制备方法和应用
IL270894B2 (en) 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
CN110175468B (zh) * 2019-05-05 2020-12-01 浙江工业大学 一种保留分布特征的姓名脱敏方法
CN115633666B (zh) * 2021-07-19 2025-11-18 四川大学华西医院 人源化双致敏动物模型和系统性过敏动物模型的构建方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
JP2002500198A (ja) 1998-01-09 2002-01-08 サーカシア リミテッド 脱感作のための方法及び組成物
FR2788698B1 (fr) 1999-01-27 2001-03-30 Commissariat Energie Atomique Peptides et proteines aptes a desensibiliser les sujets allergiques au venin d'abeille et compositions les contenant
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
ES2244708T3 (es) 2002-09-27 2005-12-16 Biomay Produktions- Und Handels- Aktiengesellschaft Vacunas hipoalergenicas contra la alergia basadas en el alergeno phl p 7 de polen de cola de zorro.
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
US20110038881A1 (en) 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
US8821887B2 (en) 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine

Also Published As

Publication number Publication date
CN102762225A (zh) 2012-10-31
SI2536429T1 (sl) 2016-08-31
GB2481475A (en) 2011-12-28
AU2011214104A1 (en) 2012-09-06
EP2536429A2 (en) 2012-12-26
HK1165700A1 (en) 2012-10-12
CN102762225B (zh) 2015-05-13
EA201290792A1 (ru) 2013-03-29
WO2011098778A3 (en) 2011-12-15
CA2789353A1 (en) 2011-08-18
GB201102657D0 (en) 2011-03-30
KR20120120965A (ko) 2012-11-02
AU2011214104B2 (en) 2015-05-28
HUE029138T2 (hu) 2017-02-28
GB2481475B (en) 2012-09-19
US9017689B2 (en) 2015-04-28
JP5926198B2 (ja) 2016-05-25
US20130243798A1 (en) 2013-09-19
MX2012009431A (es) 2012-09-12
NZ602380A (en) 2014-10-31
SG183198A1 (en) 2012-09-27
EP2536429B1 (en) 2016-02-10
ES2573651T3 (es) 2016-06-09
IL221196A0 (en) 2012-10-31
DK2536429T3 (en) 2016-05-23
WO2011098778A2 (en) 2011-08-18
GB201002559D0 (en) 2010-03-31
US20150196635A1 (en) 2015-07-16
PL2536429T3 (pl) 2016-09-30
WO2011098778A8 (en) 2012-09-27
EP3056213A1 (en) 2016-08-17
CA3139588A1 (en) 2011-08-18
JP2016166194A (ja) 2016-09-15
JP2013519717A (ja) 2013-05-30

Similar Documents

Publication Publication Date Title
HRP20171119T1 (hr) Analozi agonista receptora opioida mu endomorfina
HRP20140616T1 (hr) Peptidni analog oksintomodulina
EP2858661B1 (en) Stabilized antiviral fusion helices
HRP20191852T1 (hr) Polipeptidi
NZ703560A (en) Method for activating helper t cell
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
RU2016120641A (ru) Новые полипептиды
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
JP2010536333A5 (cg-RX-API-DMAC7.html)
PE20120021A1 (es) Mutantes fgf21
PE20121721A1 (es) Analogo peptidico de oxintomodulina
PE20140159A1 (es) Coagonistas del receptor de glucagon/glp-1
NO20090818L (no) Humant endogent retrovirus polypeptid sammensetninger samt anvendelsesmetoder derav
WO2012013979A1 (en) Anti-viral agent
RU2012123642A (ru) Аналоги инсулина, содержащие хлорированные аминокислоты
ES2673556T3 (es) Vacunas para el VHS-2
AU2018216033A1 (en) Peptide modulators of the interaction between human C-peptide and human elastin receptor for therapeutic use
SI2797950T1 (en) Fusion protein against cancer
NZ708990A (en) Method for activating helper t cell
MX2015002994A (es) Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
AR088028A1 (es) Proteinas h5, de h5n1 para un uso medicinal
WO2021181398A1 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
WO2022174768A1 (en) Anti-viral peptides and compositions and methods of use thereof